~ Dr. Jihua Cheng
Keytruda is a human programmed death receptor-1 (PD-1)-blocking antibody indicated for the treatment of patients with unresectable or metastatic melanoma and disease progression who have been treated previously with YERVOY (ipilimumab) and, if BRAF V600 mutation positive, a BRAF inhibitor, such as ZELBORAF (vemurafenib). This indication is approved under accelerated approval based on tumor response rate and durability of response. An improvement in survival or disease-related symptoms has not yet been established. CLICK HERE to learn more about Keytruda (pembrolizumab) CLICK HERE to view the FDA Approval Article regarding Keytruda (pembrolizumab) CLICK HERE to learn more about Dr. Jihua Cheng, MD PhD.